VYNE logo

VYNE Therapeutics (VYNE) Company Overview

Profile

Full Name:

VYNE Therapeutics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 25, 2018

Indexes:

Not included

Description:

VYNE Therapeutics is a biopharmaceutical company focused on developing innovative treatments for skin and autoimmune diseases. They aim to create effective therapies that improve patients' lives by using advanced science and technology to address unmet medical needs.

Key Details

Price

$2.29

Annual Revenue

$424.00 K(-11.11% YoY)

Annual EPS

-$2.78(+61.81% YoY)

Annual ROE

-47.44%

Beta

1.29

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 28, 2025

Recent annual earnings:

Feb 28, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 13, 2023

Analyst ratings

Recent major analysts updates

Feb 19, 25 HC Wainwright & Co.
Buy
Jan 14, 25 HC Wainwright & Co.
Buy
Jan 6, 25 HC Wainwright & Co.
Buy
Dec 23, 24 HC Wainwright & Co.
Buy
Nov 18, 24 BTIG
Buy
Nov 8, 24 HC Wainwright & Co.
Buy
Sep 12, 24 HC Wainwright & Co.
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
Jun 14, 24 HC Wainwright & Co.
Buy
Jun 5, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for VYNE Therapeutics?
  • Does VYNE Therapeutics pay dividends?
  • What sector is VYNE Therapeutics in?
  • What industry is VYNE Therapeutics in?
  • What country is VYNE Therapeutics based in?
  • When did VYNE Therapeutics go public?
  • Is VYNE Therapeutics in the S&P 500?
  • Is VYNE Therapeutics in the NASDAQ 100?
  • Is VYNE Therapeutics in the Dow Jones?
  • When was VYNE Therapeutics's last earnings report?
  • When does VYNE Therapeutics report earnings?
  • Should I buy VYNE Therapeutics stock now?

What is the ticker symbol for VYNE Therapeutics?

The ticker symbol for VYNE Therapeutics is NASDAQ:VYNE

Does VYNE Therapeutics pay dividends?

No, VYNE Therapeutics does not pay dividends

What sector is VYNE Therapeutics in?

VYNE Therapeutics is in the Healthcare sector

What industry is VYNE Therapeutics in?

VYNE Therapeutics is in the Biotechnology industry

What country is VYNE Therapeutics based in?

VYNE Therapeutics is headquartered in United States

When did VYNE Therapeutics go public?

VYNE Therapeutics's initial public offering (IPO) was on January 25, 2018

Is VYNE Therapeutics in the S&P 500?

No, VYNE Therapeutics is not included in the S&P 500 index

Is VYNE Therapeutics in the NASDAQ 100?

No, VYNE Therapeutics is not included in the NASDAQ 100 index

Is VYNE Therapeutics in the Dow Jones?

No, VYNE Therapeutics is not included in the Dow Jones index

When was VYNE Therapeutics's last earnings report?

VYNE Therapeutics's most recent earnings report was on Feb 28, 2025

When does VYNE Therapeutics report earnings?

The date for VYNE Therapeutics's next earnings report has not been announced yet

Should I buy VYNE Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions